Rich Pharmaceuticals is a biopharmaceutical company that is focused on the development of its lead product, TPA (12-O-tetradecanoylphorbol-13-acetate), for the treatment of acute myelogenous leukemia (AML) in refractory patients. The basis for the interest of the Company to pursue clinical development of TPA in this and possibly other indications is the result of the work of Prof. Richard Chang. He has conducted research on TPA for many years and has become an expert in the characteristics of this molecule. The findings form the scientific basis for the clinical use of TPA.